Daniel Tassé

Daniel Tassé

Lead Independent DirectoratDBV Technologies· In proxies 2023–2025

Pay in FY2025+128% from the year before · DBV Technologies stock +520.4% the same year

Daniel Tassé was paid $3.4M in FY2025 (Dec), up 128%. DBV Technologies stock rose 520.4% that year.

Pay$100 in the stock at the end of FY23 → $201
Pay is from the Summary Compensation Table of each DBV Technologies proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. RegenxbioPublic company · 3 yr
    • Lead Independent Director2023 – Present · 3 yrNo stock prices for these years
  2. DBV TechnologiesPublic company · 3 yr
    • Chief Executive Officer and Director2023 – Present · 3 yrStock in role -22%
  3. Biotechnology Industry OrganizationPublic company
    • Director? – PresentNo stock prices for these years
  4. Health SectionPublic company
    • Director? – PresentNo stock prices for these years
  5. Indivior, MrPublic company
    • Director? – PresentNo stock prices for these years
  6. Manufacturers of AmericaPublic company
    • Director? – PresentNo stock prices for these years
  7. Pharmaceutical ResearchPublic company
    • Director? – PresentNo stock prices for these years
  8. Indivior PLCPublic company · 7 yr
    • Director2014 – 2021 · 7 yrNo stock prices for these years
  9. HLS Therapeutics Inc.Public company · 1 yr
    • Director2018 – 2019 · 1 yrNo stock prices for these years
  10. Bellerophon Therapeutics, Inc.Public company · 6 yr
    • Director2013 – 2019 · 6 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?